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ABSTRACT
Topoisomerase I is essential for DNA metabolism
in nuclei and mitochondria. In yeast, a single
topoisomerase I gene provides for both organelles.
In vertebrates, topoisomerase I is divided into
nuclear and mitochondrial paralogs (Top1 and
Top1mt). To assess the meaning of this gene
duplication, we targeted Top1 to mitochondria or
Top1mt to nuclei. Overexpression in the fitting
organelle served as control. Targeting of Top1 to
mitochondria blocked transcription and depleted
mitochondrial DNA. This was also seen with
catalytically inactive Top1 mutants, but not with
Top1mt overexpressed in mitochondria. Targeting
of Top1mt to the nucleus revealed that it was
much less able to interact with mitotic chromo-
somes than Top1 overexpressed in the nucleus.
Similar experiments with Top1/Top1mt hybrids
assigned these functional differences to structural
divergences in the DNA-binding core domains. We
propose that adaptation of this domain to different
chromatin environments in nuclei and mitochondria
has driven evolutional development and conser-
vation of organelle-restricted topoisomerase I
paralogs in vertebrates.
INTRODUCTION
Replication and transcription of nuclear and mitochon-
drial genomes create DNA-topological stress that needs
to be released in order to allow these DNA metabolic
processes to proceed. Therefore, the ability of DNA
topoisomerases (Top) to release topological stress from
DNA is essential in the nuclear as well as the mitochon-
drial compartment (1). Topoisomerases employ transient
breakage and religation of either one (Top1 and Top3) or
both DNA strands (Top2) to allow swiveling of or strand
passage through the double helix, thereby changing DNA
topology (2).
Five diﬀerent enzymes (Top1, Top2a, Top2b, Top3a
and Top3b) provide topoisomerase activity for the
nucleus of vertebrate cells. Two of these are also
targeted to the mitochondria via posttranscriptional
mechanisms: mitochondrial Top3a is created by alterna-
tive translation initiation of the same mRNA that encodes
nuclear Top3a (3); mitochondrial Top2 seems derived
directly from the nuclear enzyme Top2b by proteolysis
(4). In contrast, the nuclear and mitochondrial versions
of topoisomerase I (Top1 and Top1mt) are encoded by
separate genes (5).
Duplication and diversiﬁcation of the TOP1 gene into
nuclear and mitochondrial paralogs is conserved in verte-
brates, whereas invertebrate eukaryotes do not possess a
genetically distinct, mitochondria-targeted topoisomerase
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tional in nuclei and mitochondria of invertebrates,
because genetic silencing of the single TOP1 gene in
Saccharomyces cerevisiae suppresses mitochondrial
Top1 activity (8,9). In silico analysis predicts that the
single Top1 form of Schizosaccharomyces pombe is also
targeted to nuclei and mitochondria (3). It is unclear
why vertebrates do not employ the same topoisomerase
I in nuclei and mitochondria and instead maintain genet-
ically distinct paralogs of the enzyme dedicated to either
organelle. Transcription and replication machineries
acting on mitochondrial DNA (mtDNA) diﬀer signiﬁ-
cantly between yeast and mammals (10). Therefore, evo-
lution of multicellular organisms could have required the
development of a specialized Top1mt with properties
distinct from its nuclear counterpart. On the other hand,
diﬀerences in nuclear chromatin organization known
to exist between yeast and mammals could have incited
the development of a topoisomerase I that is adapted to
nuclear DNA metabolism but incompatible with mtDNA
maintenance.
Here, we investigated the biological meaning of the
duplication of the topoisomerase I gene into TOP1 and
TOP1mt by studying mitochondria-targeted Top1 and
nuclear-targeted Top1mt in human cells. We demonstrate
that Top1 and Top1mt diﬀer signiﬁcantly in their interac-
tion with nuclear and mtDNA. This diﬀerence is encoded
in the core domain of the two enzymes. As a consequence,
Top1 is incompatible with stable mtDNA propagation,
while Top1mt is incapable of interacting with nuclear
metaphase chromosomes.
MATERIALS AND METHODS
DNA constructs
For mitochondrial targeting of ﬂuorescent fusion proteins,
YFP in the vector pMC-EYFP-N (11) was extended in
frame at the 50-end with the sequence encoding the
mitochondrial targeting sequence (MTS) from subunit
VIII of cytochrome C oxidase (COX) (12) using linker
PCR, thus generating pMC-MTS-EYFP-N. Likewise,
the coding sequence for Top1mt (5) was inserted in
frame at the C-terminal end of MTS-YFP. For
mitochondrial targeting of Top1, its open reading frame
was cloned into the MluI and ApaI sites of the pMC-
MTS-EYFP-N vector. Variants of this vector, containing
truncated versions of Top1 (Top1
191–765 and the corre-
sponding active site mutant (Y723F) Top1
191–765 ) were
constructed in the same way. Exchange of regions
between Top1 and Top1mt was accomplished by
overlap-extension PCR (13). For nuclear localization of
Top1mt and chimeric Top1mt/Top1, their open reading
frames were supplemented with the nuclear localization
signal (NLS) of SV40. Construction and characterization
of vectors for stable expression of YN-Top1
191–765 have
been described previously (14,15). For lentiviral expres-
sion of MY or MY-Top1 in HT-1080 cells, the sequences
were cloned into the lentiviral pCL1P vector. The pCL1P
is a derivative of the pCL1EG vector (16), in which the
EGFP open reading frame was replaced by the selection
marker puromycin-N-acetyl transferase and a multi-
cloning site (BamHI-ClaI-EcoRI-AgeI-NheI-XhoI-PstI)
introduced between the lentiviral cPPT and the internal
SFFV U3 promotor.
Cell culture
Transfections and selection of HT-1080 cells (German
Collection of Microorganisms and Cell Cultures,
Braunschweig, Germany) followed published procedures
(15). Cells were selected using 0.6mg/ml puromycin and
grown in DMEM supplemented with 50mg/ml uridine, if
not speciﬁed otherwise. For each construct, at least 12 cell
clones supporting stable expression of the desired fusion
proteins were picked and expanded. For the preparation
of virus particles, vector plasmids pCL1 (5mg), helper
plasmid pCD/NL-BH (5mg) and the envelope plasmid
pczVSV-Gwt (5mg) (17) were cotransfected into HEK-
293T cells using polyethylene (Sigma, Taufkirchen,
Germany). The virus stocks were harvested 48h after
transfection, ﬁltered (0.45mm) and stored at –80 C. HT-
1080 cells were transduced and medium was replaced 12h
after transduction with fresh medium containing 50mg/ml
uridine and 0.6mg/ml puromycin.
Cell growth and cell-cycle analysis
For determination of cell growth, cells were repeatedly
split 1:2 upon conﬂuency. Cell cycle progression was mon-
itored using a ﬂow cytometer (FACSCalibur, BD
Bioscience, Heidelberg, Germany). Brieﬂy, cells were
harvested and ﬁxed in 70% ethanol, treated with 50mg/
ml RNAse and DNA was stained with 50mg/ml
propidium iodide. A total of 10000 cells per sample
were analyzed.
Life cell imaging and senescence-associated
b-galactosidase staining
Live cell imaging was done with a Zeiss LSM 510 META
inverted confocal laser-scanning microscope equipped
with a Zeiss incubator XL and a 40x/1.3NA Plan-
NeoFluar oil immersion objective. Cells were cultured
under the microscope in CO2-independent medium
(18045-045, Invitrogen, Karlsruhe, Germany). For visual-
ization of mitochondria, cells were incubated for 5min
with 10nM MitoTrackerRed CMXRos (Invitrogen),
washed with PBS and then supplied with fresh medium
prior to inspection. Staining for b-galactosidase was
done as described (18) and pictures were taken with
a Zeiss Axiovert135 microscope with a 20x/1.3
Apochromat objective.
Preparation of whole cell or mitoplast lysates and
immunoblotting
Whole cell lysates were prepared from 3 10
6cells as
described previously (19). To isolate the inner-membrane
mitochondrial fraction (mitoplast), a protocol for mito-
chondria isolation (20) was modiﬁed by addition of
digitonin, a detergent disrupting all cellular membranes
except the inner mitochondrial membrane. Brieﬂy, cells
from two conﬂuent 175 cm
2 tissue culture ﬂasks were
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resuspended in 5ml mitochondria isolation buﬀer (0.3M
sucrose, 1mM EGTA, 5mM MOPS, 5mM KH2PO4,
1mg/ml BSA, pH 7.4) supplemented with 0.1mg/ml
digitonin, incubated for 10min, homogenized with 25
strokes in a Dounce homogenizer and centrifuged twice
at 2600g for 7min. The supernatant was centrifuged
at 15000g for 10min and pelleted mitoplasts were
resuspended in 0.1ml mitochondria isolation buﬀer
without digitonin. All steps were performed on ice.
Mitoplast lysates were prepared by addition of an equal
volume of 2-fold lysis buﬀer (250mM Tris–HCl, pH 6.8,
2% glycerol, 4% SDS, 20mM DTT, 1.4M urea, 20mM
EDTA, 5mM AEBSF, 0.04% bromophenol blue). Cell or
mitoplast lysates equivalent to 10
5cells were subjected
to SDS–PAGE, and transferred to PVDF membranes
(Immobilon P, Millipore, Bedford, MD). Blots were
probed with antibodies against YFP (clone JL8,
Clontech, Heidelberg, Germany).
Banddepletion assay
For immunoband depletion, cells were ﬁrst cultured with
100mm topotecan (TPT) for 30min prior to harvesting.
The same concentration of drug was also added to the
lysis buﬀer.
Mitoplast extraction and plasmid relaxation
Mitoplasts were extracted for 10min at 4 C (0.3M
sucrose, 500mM NaCl, 1mM EGTA, 5mM Mops,
5mM KH 2PO4, 0.25mM AEBSF, 0.5mM DTT, 0.1%
Triton, 1mg/ml BSA, pH 7.4). Extracts were cleared
(15000g, 10min), and total protein concentrations were
adjusted to 1.7mg/ml. Extracts were diluted 10-fold with
relaxation buﬀer (10mM Tris–HCl, pH 8, 70mM KCl,
3mM MgCl2, 0.3mM EDTA, 0.3mg/ml BSA and
0.5mM DTT) and 170ng total protein were incubated
with 0.4mg supercoiled pUC18 DNA at 37 C. Reactions
were stopped by adding 0.5% SDS. Samples were further
analyzed as described (21).
MtDNA copy number
Total DNA was isolated using QIAamp DNA Blood Mini
Kit (Qiagen, Hilden, Germany). MtDNA copy number
was determined according to the quantitative TaqMan-
PCR method (22). Brieﬂy, 100ng total DNA was sub-
jected to ampliﬁcation reactions performed as 25ml
duplicates in a 96-well microplate with a forward
primer (50-GATTTGGGTACCACCCAAGTATTG-30)
and a reverse primer (50-TTGACTCACCCATCAACAA
CC-30), each recognizing a unique mtDNA sequence. To
determine the abundance of mtDNA in the sample, ampli-
ﬁcation was performed in parallel with diﬀerent concen-
trations of standard plasmids.
2D neutral agarose gel electrophoresis and Southern
blotting
For analysis of replication intermediates (RIs), mito-
chondria were isolated and mtDNA prepared as described
(23). For 2D neutral agarose-gel electrophoresis, 1.5mgo f
mtDNA was digested with HincII. The ﬁrst dimension
was run in a 0.4% agarose gel in TBE buﬀer, and the
second dimension was run with 0.1% EtBr in a 0.95%
agarose gel in TBE. Southern blotting was carried
out using standard procedures (23). The fragment
13636-1006bp containing the control region was
detected by hybridization with a
32P-labeled cytochrome
b probe (nucleotides 14846–15358) (23).
RNA extraction and quantiﬁcation of mitochondrial
transcripts by RT-PCR
Total RNA was isolated using RNeasy Mini Kit (Qiagen)
according to manufacturer’s instructions. For quality
assurance, the RNA integrity was determined with the
Agilent 2100 Bioanalyzer (RNA 6000 LabChip, Agilent
Technologies, Waldbronn, Germany). Quantitative
RT-PCR reactions were performed in duplicates in a
reaction volume of 25ml using the QuantiTect SYBR
Green one-step RT-PCR Kit (Qiagen). COXI and 12S
rRNA, were ampliﬁed from 5ng total RNA, whereas
5pg samples were used for quantiﬁcation of the internal
standard 18S rRNA. Used primer pairs: COXI (50-TACC
TATTATTCGGCGCATGAGCTGGA-30,5 0-TGCATG
GGCTGTGACGATAACGTTGTA-30), 12S rRNA
(50-GGTTGGTCAATTTCGTGCC-30,5 0-GAGTTTTTT
ACAACTCAGGTG-30), SDHB (50-AGTTGACTCTAC
TTTGACCTTCCGAAG-30,5 0-GACCTTATTGAGGTT
GGTGTCAATCCT-30) and 18s rRNA (50-ATTAGAGT
GTTCAAAGCAGGCCCGAGC-30,5 0-CGTCCCTCTT
AATCATGGCCTCAGTTC-30;o r5 0-GTCCAAAGCA
GGCCCGAG-30,5 0-CCCTCTTAATCATGGCCTC-30).
For quantiﬁcation, standard plasmids were used, which
contained the ampliﬁed gene sequences in a pCR2.1-
TOPO vector (Invitrogen).
Modeling of the Top1 structure
Cartoon ribbon drawings of the X-ray crystal structure
(PDB entry 1K4T) by Staker et al. (24) were created
using the MACPyMOL software (Delano Scientiﬁc LLC).
Statistics
Quantitative results are given as mean values±SEM of
multiple measurements carried out with independent cell
clones expressing the same construct. The actual number
of clones investigated is stated in each ﬁgure. Data sets
were compared by the t-test for unpaired samples.
P<0.05 was considered signiﬁcant.
RESULTS
Constitutive expression of mitochondria-targeted
constructs of Top1 in HT-1080 cells
In order to simultaneously target and track Top1 and
variants thereof, we generated constructs for the expres-
sion of N-terminal YFP-tagged proteins with a MTS from
COX subunit VIII (Figure 1A). Mitochondrial targeting
was performed for full-length Top1 (MY-Top1) and a
N-terminally truncated version, in which residues 1–190
were deleted (MY-Top1
191–765). The truncated version is
6416 Nucleic Acids Research, 2009,Vol.37, No. 19devoid of all NLSs (25,26). MY-Top1
191–765 closely
resembles Top1mt, since it lacks most amino acids
encoded by the ﬁrst eight exons of the TOP1 gene
(residues 1–205), which are unique to Top1 (7). The
active site tyrosine (Y723F) in MY-Top1
191–765 was
replaced with phenylalanin to generate a catalytically
inactive enzyme (MY-Top1
191–765 ). The MY tag was
also appended at the N-terminus of Top1mt (MY-
Top1mt). The basic vector encoding for mitochondria-
targeted YFP alone (MY) served as control for an inert
protein not binding DNA. When transfected into human
HT-1080 cells, all constructs gave rise to viable cell clones.
Clones expressing MY or MY-Top1mt exhibited growth
rates and gross morphologies similar to untransfected
cells. Cells expressing any of the mitochondria-targeted
versions of Top1 (including the inactive mutant MY-
Top1
191–765 ) were growth-arrested, unless the culture
media was supplemented with uridine (see below).
To assess the integrity and mitochondrial targeting of
the fusion proteins, we subjected whole cells and isolated
mitoplasts (mitochondrial matrix surrounded by the inner
membrane) to immunoblotting with YFP antibodies. MY
and MY-Top1mt were detected as single protein bands
of expected size in lysates of whole cells and mitoplasts
(Figure 1B). Mitochondria-targeted versions of Top1 were
detected in lysates from whole cells as a protein doublet,
of which only the faster migrating band was detected in
corresponding mitoplast lysates (Figure 1B). The slower
migrating band probably represents a protein fraction not
imported into mitochondria and still possessing the MTS
presequence. Consistent with this, YFP-ﬂuorescence
of these fusion proteins was not only exclusively localized
in mitochondria, but also found in the nucleus to various
extents (see Figure 2A and Supplementary Figure 1).
In the case of MY-Top1 bearing multiple endogenous
NLSs in the N-terminal domain (25,26) and showing a
prominent nuclear localization, the slower migrating
band is the prevalent one. In contrast, the faster migrating
band was predominant in all mitochondria-targeted
constructs of Top1 lacking major portions of the
N-terminal domain and exhibiting only a weak nuclear
localization (MY-Top1
191–765 and MY-Top1
191–765 ).
It should ﬁnally be noted that all fusion proteins were
expressed at similar levels which allowed their compara-
tive analysis.
To ascertain that topoisomerase I constructs were active
after mitochondrial import, we measured their DNA
relaxation activity in salt extracts of isolated mitoplasts.
Mitoplast extracts from cells expressing MY or the
catalytically inactive mutant MY-Top1
191–765  exhibited
only a very weak DNA relaxation activity, which was
similar to that found in untransfected cells (data not
shown) and probably due to endogenous Top1mt
(Figure 1C). Extracts from cells expressing MY-Top1mt
or MY-Top1
191–765 exhibited enhanced DNA relaxation
activity. A comparable increase in DNA relaxation
activity was observed in mitoplast extracts from cells
expressing MY-Top1 (data not shown). Thus, mitochon-
drial targeting did not compromise catalytic activity of the
respective topoisomerase I constructs.
Targeting of Top1 to mitochondria induces mtDNA
depletion and a q
  phenotype
Subcellular localization of the various mitochondria-
targeted topoisomerase I constructs and their impact on
mitochondrial morphology was studied by live cell
confocal microscopy. Staining of untransfected HT-1080
cells with the mitochondria-speciﬁc dye MitoTracker
revealed mitochondria forming a largely connected
reticulum typical of mammalian cells [Figure 2A; (27)].
A similar pattern was seen in cells expressing MY or
MY-Top1mt. YFP ﬂuorescence corresponding to MY
Figure 1. Expression and activity of mitochondria-targeted YFP fusion
proteins. (A) Schematic outline of constructs: MTS-YFP (MY);
MTS-YFP-Top1mt (MY-Top1mt); MTS-YFP-Top1 (MY-Top1);
MTS-YFP-Top1
191–765 (MY-Top1
191–765); and MTS-YFP-Top1
191–765,
Y723F (MY-Top1
191–765 ). All constructs contained a MTS. Top1 and
Top1mt indicate the nuclear and mitochondrial paralogs, respectively;
MY-Top1
191–765  is a catalytically inactive Top1 mutant (Y723F).
(B) Western blot analysis of lysates from whole cells (WC) or
isolated mitoplasts (M) from representative HT-1080 cell clones
expressing the constructs indicated above. Samples were subjected to
SDS–PAGE (left, 12% gel; right, 5.5% gel) and western blotting using
YFP antibodies. Proteins with (arrow) or without presequence (arrow-
head) are indicated. (C) Relaxation over time of supercoiled pUC18
plasmid DNA by mitoplast extracts (170ng total proteins) prepared
from cell clones expressing the indicated constructs. Positions of
relaxed (RL) and supercoiled (SC) plasmid forms are indicated on
the right. Time points 0 represent DNA not exposed to mitoplast
extracts.
Nucleic Acids Research, 2009,Vol.37, No. 19 6417Figure 2. In vivo localization of mitochondria-targeted YFP fusions proteins. Each row shows representative confocal images of living cells stably
(A) or transiently (B) expressing the indicated constructs. Shown are images of transmitted light, YFP- and MitoTrackerRed ﬂuorescence. Merged
signals of YFP- and MitoTrackerRed ﬂuorescence in the indicated areas are shown at 3-fold magniﬁcation (right).
6418 Nucleic Acids Research, 2009,Vol.37, No. 19and MY-Top1mt largely coincided with MitoTracker
staining, which conﬁrmed complete mitochondrial
import of these proteins. Merged and enlarged pictures
revealed that MY had a diﬀuse homogenous
mitochondrial distribution, which was similar to
MitoTracker and consistent for a protein not interacting
with mitochondrial structures. In contrast, MY-Top1mt
accumulated at speckles within the mitochondrial com-
partment (Figure 2A). Counterstaining of DNA con-
ﬁrmed that these speckles were identical or associated
with mitochondrial nucleoids (data not shown), indicating
proper incorporation of MY-Top1mt into its native
microenvironment.
MY-Top1 as well as active and inactive truncated
variants thereof (MY-Top1
191–765 and MY-Top1
191–765 )
were also localized in mitochondria (Figure 2A). MY-
Top1 showed a dual localization in mitochondria and cell
nucleus due to multiple NLSs in the N-terminal domain
(25,26). Truncation of this domain in the constructs MY-
Top1
191–765 and MY-Top1
191–765  induced a predominant
mitochondrial localization with only traces of nuclear
staining remaining detectable (Supplementary Figure 1).
Most notably, all three constructs derived from Top1
induced rounded and ballooned mitochondria with
enhanced fragmentation (Figure 2A). A similar morphol-
ogy has previously been observed in q
  cells depleted of
mtDNA (28). This coincidence suggests that targeting of
Top1 to mitochondria could induce a loss of mtDNA. This
notion is also supported by the observation that all
constructs derived from Top1 were diﬀusely distributed
in mitochondria and not accumulated in speckled
substructures, possibly indicating an absence of nucleoids
in these mitochondria (Figure 2A). Additional phenotypic
similarities between q
  cells and cells expressing
mitochondria-targeted Top1 are summarized in the data
supplement: both cell types require uridine
supplementation for growth due to a deﬁciency in
de novo pyrimidine synthesis [(29); Supplementary Figure
2A]. In the absence of uridine, they are arrested in G2
phase, have elevated levels of polyploid and hypodiploid
cells (30) (Supplementary Figure 2C) and exhibit features
of cellular senescence such as enhanced activity of
senescence-associated b-galactosidase and increased cell
size [(30); Supplementary Figure 2B].
To analyze whether mtDNA content was indeed
aﬀected by the continuous expression of mitochondria-
targeted Top1 constructs, we performed quantitative
PCR experiments. As summarized in Table 1, mtDNA
content was not altered in cells overexpressing MY-
Top1mt as compared with control cells expressing
MY alone. Mitochondrial targeting of full-length Top1
(MY-Top1) led to a strong depletion of mtDNA. This
eﬀect was also seen with the N-terminally truncated
Top1 (MY-Top1
191–765) or the active site mutant (MY-
Top1
191–765 ). These data demonstrate that a continued
presence of Top1 in the mitochondrial matrix results in
a complete loss of mtDNA and that this eﬀect does not
rely on catalytic activity or the N-terminal domain, which
is the most distinctive structural feature of the nuclear
paralog.
Association of MY-Top1
191–765 with mitochondrial
nucleoids precedes mtDNA depletion
Because the results up to here stem from stably transfected
cell clones, they describe an endpoint where mtDNA
was terminally depleted. Therefore, they do not allow
conclusions regarding the process leading to this
endpoint. It remains unclear whether mtDNA depletion
occurs instantaneously or gradually, whether it is a direct
eﬀect due to active degradation of mtDNA by Top1
constructs and whether the nuclear enzymes associated
with mtDNA and nucleoids in the same way as MY-
Top1mt (Figure 2A). To address these questions, we
studied localization of MY-Top1mt and MY-Top1
191–765
by transient transfection. Thirty-six hours after
transfection, MY-Top1mt accumulated at mitochondrial
speckles in a pattern similar to constitutively expressing
cells clones (compare Figure 2B with A). Within the same
time frame of transient expression, MY-Top1
191–765
concentrated at nucleoid-like speckled structures in a
fashion similar to MY-Top1mt. This is clearly diﬀerent
from the homogeneous distribution of MY-Top1
191–765
seen upon stable expression (compare Figure 2B with A),
suggesting that the enzyme interacts with mtDNA prior to
inducing its depletion. It should also be noted that
36h after transient transfection with MY-Top1
191–765, the
morphology of mitochondria was already disordered to
some extent (Figure 2A and B). To ascertain that the mito-
chondrial portion of MY-Top1 indeed interacts with
mtDNA during transient expression, we treated the cells
with TPT, a speciﬁc topoisomerase I poison known to
access both nuclear and mitochondrial compartments
(31) and to stabilize the transient covalent complexes
between Top1 and DNA. Since such complexes are
retained in the gel slots, Top1-speciﬁc signals get
depleted from immunoblotting analysis upon eﬀective
interaction of the enzyme with DNA and TPT. Therefore,
interactions of MY-Top1 with mtDNA should be detect-
able as TPT-inducible depletion of the lower protein band
presumably corresponding to the mitochondrial portion of
the enzyme. As shown in Figure 3, this was indeed the case
in cells transiently expressing MY-Top1. Both bands
were depleted upon TPT treatment suggesting that the
enzyme was actively engaged in DNA catalysis in the
nucleus and the mitochondria. In contrast, TPT treatment
Table 1. MtDNA depletion in cells expressing topoisomerase I
constructs
Constructs MtDNA copies
(±SEM)
Number of
clones
investigated
P-value
MY 1.0±0.33 13 –
MY-Top1mt 0.94±0.25 27 –
MY-Top1 7.23 10
 5±5.56 10
 5a 2 <0.0001
MY-Top1
191–765 1.97 10
 4±3.0 10
 4a 3 <0.0001
MY-Top1
191–765  1.19 10
 4±2.59 10
 5a 3 <0.0001
MtDNA copy numbers were determined by quantitative real time PCR.
aValues diﬀered signiﬁcantly from the control (MY) according to an
unpaired t-test. Values of control cells (MY) were arbitrarily set to 1.0.
Nucleic Acids Research, 2009,Vol.37, No. 19 6419of cells constitutively expressing MY-Top1 (and devoid of
mtDNA) only led to a depletion of the upper protein band
corresponding to the nuclear portion of enzyme, whereas
the lower band representing mitochondrial located enzyme
was not diminished. Taken together, these ﬁndings indicate
that upon targeting to mitochondria Top1 indeed interacts
with mtDNA, which possibly triggers mtDNA depletion
occurring subsequently.
Nuclear topoisomerase I depletes mtDNA via blockade
of RNA transcription
For a more precise analysis of the time course of mtDNA
depletion, we transduced HT-1080 cells with lentiviral-
based vectors facilitating expression of MY alone or
MY-Top1, and monitored cellular mtDNA content
during subsequent cell population doublings (PDs). To
avoid growth arrest, cells were supplemented with
uridine at all times. During the ﬁrst two PDs, mtDNA
copy number was not signiﬁcantly diminished by expres-
sion of either construct (Figure 4A). Subsequently, it
remained unchanged in MY-expressing control cells,
whereas it declined exponentially in cells expressing MY-
Top1 (Figure 4A). The delay in onset of mtDNA deple-
tion excluded that MY-Top1 directly blocked mtDNA
replication or actively degraded mtDNA. The exponential
manner of subsequent mtDNA depletion suggested rather
a mechanism related to cell doubling. Overall, the time
course of mtDNA depletion in cells expressing MY-
Top1 was best approximated by a model (Figure 4A),
assuming a lag phase of  2 PD followed by a exponential
decay phase, in which mtDNA replication was abolished
and mtDNA was reduced 2-fold after each cell division.
These ﬁndings suggested an indirect eﬀect of Top1 on
mtDNA replication. One mechanism compatible with this
would be blockade of mtDNA transcription, which is con-
nected to mtDNA replication, because the transcription
Figure 4. MY-Top1-mediated inhibition of mtDNA transcription precedes mtDNA loss. (A) Kinetics of mtDNA loss. Mitochondria-targeted YFP
alone (open circles) or MY-Top1 (closed circles) were expressed in HT-1080 cells through a lentiviral vector system. Transduced cells were grown in
the presence of uridine, and mtDNA copy numbers were determined after each PD. Time zero ( 24h after infection) was deﬁned as the moment at
which YFP ﬂuorescence became detectable in mitochondria by ﬂuorescence microscopy and western blotting (data not shown) and in all cultures
used, at least 99% of the cells were YFP positive. The full line represents the regression of experimentally determined mtDNA copy numbers from
PD 2–6. The hatched line represents a one phase exponential decay (N=N0e
 kt) resulting from a theoretical 2-fold dilution of mtDNA after each
cell division. (B) Kinetics of mtRNA loss. In parallel to the mtDNA quantiﬁcation in (A), COXI mRNA was determined by quantitative RT-PCR
and normalized to the level of 18S rRNA in cells expressing MY (open squares) or MY-Top1 (closed squares). (C) Analysis of mtDNA RIs. 2D
neutral agarose gel electrophoretic analysis of mtDNA isolated from cells expressing MY at PD 3 (top right) or MY-Top1 at PD 0 (bottom left) and
PD 3 (bottom right). The mtDNA was digested with HincII and the fragment containing the control region was detected with a radioactively labeled
cytochrome b probe. Positions of bubble arcs (initiation of replication) and the y-arc (ongoing replication) are indicated by arrowheads and arrows,
respectively. Schematic illustration of detected RIs (top left): spot (1n), fragments not being replicated; the bubble arcs (b), indicative of fragments
with replication initiation; the y-arc (y), fragments on which the replication machinery passes through; positions of RNA-containing RIs are depicted
in gray.
Figure 3. MY-Top1 interacts with mtDNA prior to inducing its deple-
tion. Immunoband depletion assay of cells stably or transiently
expressing MY-Top1. Lysates of whole cells were subjected to SDS–
PAGE (5.5% gel) and western blotting. Blots were probed with YFP
antibodies. Cells were cultured in absence ( ) or presence of 100mM
TPT (+) for 30min before lysis.
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tion initiation (10,32). Thus, a strong inhibition of
mitochondrial transcription could eventually abolish
mtDNA replication. To investigate this possibility, we
determined the levels of mtRNA transcripts during
MY-Top1-induced mtDNA depletion. Expression of
MY-Top1 induced a reduction of COXI mRNA levels
by  77,  94,  98 and >99% after 1, 2, 3 and 4 PDs,
respectively (Figure 4B). Similar depletion kinetics were
observed for mitochondrial 12S rRNA (data not shown).
In contrast, MY alone had no such eﬀect (Figure 4B).
Comparison of the depletion kinetics of mtDNA and
mtRNA transcripts revealed that expression of MY-
Top1 inhibited mtDNA transcription instantaneously,
whereas reduction in mtDNA copy numbers followed
one or two PDs later. Treatment with the speciﬁc
mtDNA replication inhibitor dideoxycytidine (33)
showed a reverse order of mtDNA and mtRNA depletion,
and treatment with ethidium bromide that inhibits tran-
scription and replication (34) simultaneously induced
depletion of mtDNA and mtRNA (Supplementary
Figure 3A and B). These experiments show that the
kinetics of inhibition of mtDNA transcription and repli-
cation were clearly distinct and that mitochondrial target-
ing of Top1 ﬁrst induced a strong inhibition of mtDNA
transcription followed by a gradual decline in mtDNA
content.
Because mitochondrial targeting of Top1 induced
instant depletion of mtRNA and a delayed depletion of
mtDNA, we hypothesized that these eﬀects could be
caused by an inhibition of RNA-primer synthesis
required for mtDNA replication. An implicit prediction
of this hypothesis is that, upon mitochondrial targeting
of Top1, initiation of mtDNA replication should become
suppressed, whereas the already initiated replication pro-
cesses continue until completion. We, therefore, analyzed
replication intermediates (RIs) of mtDNA after expression
of MY-Top1. To this end, the major noncoding region of
mtDNA, containing the principal initiation and termina-
tion sites for replication, was released by digestion with
HincII and after separation by 2D neutral agarose gel
electrophoresis detected in Southern blots with a
cytochrome b probe. During the ﬁrst PD, when cells
expressing MY-Top1 had not yet entered the mtDNA
depletion phase, the bubble arcs, indicative of replication
initiation, became signiﬁcantly reduced as opposed to cells
expressing MY (Figure 4C). At this stage, the y-arc, indic-
ative of ongoing replication, was only marginally reduced.
These diﬀerences became more pronounced during the
phase of exponential mtDNA depletion, when the
bubble arcs as well as the y-arc were completely lacking
(Figure 4C). RIs indicative of stalled replication forks
were absent at all stages, conﬁrming that Top1 inhibited
the initiation of mtDNA replication but not the continu-
ation of started replication forks.
MtDNA depletion is linked to the N-terminal portion
of the core domain of Top1
Our observation that Top1 is incompatible with stable
mtDNA propagation suggests that the two genetically
distinct paralogs of topoisomerase I have undergone evo-
lutionary specialization to the divergent requirements of
nuclear and mitochondrial genomes. To determine which
evolutionary modiﬁcations of the primary structure were
crucial in this, we expressed hybrid proteins in which
corresponding regions were exchanged between Top1
and Top1mt. In order to simplify, we here designated
residues 191–634 of Top1 as the core domain. By this
deﬁnition, the core includes a part (residues 191–210) of
the N-terminal domain. Sequence alignment identiﬁed the
N-terminal half of the core domain and a C-terminal
region encompassing linker and C-terminal domains as
regions with the greatest sequence diﬀerences between
Top1 and Top1mt [55 and 64% identical residues, respec-
tively, Figure 5A; (6,7)]. These regions were selected for
exchange. The construct MY-Top1mt
1–470/Top1
635–765 is
identical to Top1mt up to residue 470 and then continues
with residues 635–765 of Top1 (Figure 5B, left), whereas
MY-Top1mt
1–187/Top1
352–765 contained residues 1–187 of
Top1mt followed by residues 352–765 of Top1. We also
exchanged the divergent N-terminal half of the core
domain by replacing residues 1–187 in Top1mt with
191–351 of Top1 creating MY-Top1
191–351/Top1mt
188–601. These constructs were transfected into HT-1080
cells, and several cell clones with stable expression were
selected. Immunoblotting and measurement of DNA
relaxation activity conﬁrmed that the expressed proteins
were of correct size and catalytically active (Supple-
mentary Figure 4A and B). Furthermore, confocal ﬂuo-
rescence microscopy veriﬁed their mitochondrial
localization (Supplementary Figure 4C). In conclusion,
the hybrid proteins were imported into mitochondria,
correctly folded and active.
Analysis of the eﬀects of these constructs on mtDNA
content revealed that cells expressing the hybrid MY-
Top1mt
1–470/Top1
635–765, where the C-terminal end of
Top1mt was replaced with a corresponding Top1
sequence, displayed no signiﬁcant reduction of mtDNA
levels (Figure 5B, right). Even extending the exchange
position into the middle of the DNA-binding core
domain (MY-Top1mt
1–187/Top1
352–765) resulted only in a
minor reduction of mtDNA copy numbers. However,
replacement of the N-terminal half of the Top1mt core
domain with the corresponding portion of the nuclear
enzyme (MY-Top1
191–351/Top1mt
188–601) resulted in
complete depletion of mtDNA (Figure 5B). Thus,
mtDNA-repressive properties of Top1 are fully retained
in hybrids bearing the N-terminal half of the core domain
of Top1 (residues 191–351), whereas replacement of all
other residues of Top1 with corresponding Top1mt
regions failed to induce mtDNA depletion.
Nevertheless, it remained unclear whether the mtDNA-
repressive eﬀect is a property of the N-terminal half of the
Top1 core domain itself or exerted only when this region is
placed in the context of a complete topoisomerase I
enzyme. To investigate this, we targeted C-terminal
truncations of Top1 to mitochondria. One construct
(MY-Top1
191–351) was truncated behind residue 351 and
thus only contained the minimal region of Top1 confer-
ring the complete mtDNA-repressive eﬀect (Figure 5C).
Since this fragment constitutes the entire core subdomain
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core subdomain III of Top1 (2), it was uncertain if it
would fold into a proper Top1-substructure. Therefore,
we created a second construct containing the entire core
and part of the linker domain (MY-Top1
191–659). This
second Top1 fragment is catalytically inactive but its
activity can be reconstituted in vitro by addition of a
recombinant fragment encompassing residues 658–765
Figure 5. MtDNA depletion is inﬂicted by residues 191–351in Top1. (A) Comparison of human Top1mt (white) and Top1 (gray). Topoisomerase I
is composed of N-terminal, core, linker and C-terminal domains as indicated above. Numbers indicate the residues ﬂanking the sites chosen for
exchanging regions between Top1 and Top1mt. Amino acid identities and similarities for each region are indicated below. For simplicity, residues
191–634 are designated in the present study as the core domain. (B) MtDNA copy numbers in cell clones expressing Top1/Top1mt hybrids. Left:
schematic synopsis of hybrid constructs. All constructs were fused to MY at their N-terminal end: MY-Top1mt
1–470/Top1
635–765; MY-Top1mt
1–187/
Top1
352–765; and MY-Top1
191–351/Top1mt
188–601. Right: mtDNA copy numbers in cell clones expressing the constructs indicated on the left were
determined using quantitative PCR. Values were normalized to the mean value of clones expressing MY alone, which was arbitrarily set to 1.0.
Number of clones investigated is indicated (n), and error bars indicate the SEM. Signiﬁcant diﬀerences between each bar and the control cells MY
are marked with asterisks (
 P<0.05,
   P<0.0001) according to an unpaired t-test. (C) MtDNA copy numbers in cell clones expressing C-terminally
truncated versions of Top1. Left: schematic synopsis of MY-Top1
191–351 and MY-Top1
191–659. Right: mtDNA copy numbers determined as in B.
(D) Homogenous mitochondrial distribution of MY-Top1
191–351 and MY-Top1
191–659. Shown are confocal images of transmitted light (left panel),
YFP ﬂuorescence (middle left panel), MitoTrackerRed ﬂuorescence (middle right panel) and merged signals of latter two restricted to the area
indicated in the MitoTrackerRed column at 3-fold magniﬁcation (right panel).
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functional substructure of the Top1 molecule. However,
neither MY-Top1
191–351 nor MY-Top1
191–659 depleted
mtDNA (Figure 5C, right) indicating that the mtDNA-
repressive potential residing in residues 191–351 of Top1 is
only exerted, when this portion is embedded in the entire
context of core-, linker- and C-terminal domains of the
enzyme.
Together these three domains form a bi-lobed protein
that clamps around DNA [See illustration in Figure 7A;
(2,24)]. Top1 reconstituted by mixing two recombinant
fragments encompassing the three domains (Top1
175–659
+Top1
658–765) is active but has a  20-fold lower DNA
aﬃnity than the holoenzyme (35). This is thought to
indicate the importance of the C-terminal domain
for enabling Top1 to clamp around the DNA. MY-
Top1
191–659 lacking the C-terminal domain is probably
unable to interact with mtDNA and therefore unable to
repress mtDNA. If this reasoning was correct,
C-terminally truncated Top1 constructs should not
notably accumulate at mitochondrial nucleoids. As
shown in Figure 5D, this was indeed the case for MY-
Top1
191–351 and MY-Top1
191–659. Both were homogen-
ously distributed within the mitochondria and did not
exhibit any signs for a speckled accumulation within the
mitochondrial matrix. This is in clear contrast with
constructs having the entire C-terminal domain such as
MY-Top1mt and MY-Top1
191–765 (under conditions of
transient expression), which have a speckled distribution
reﬂecting association with nucleoids (Figure 2). Therefore,
in the case of MY-Top1
191–351 and MY-Top1
191–659, the
absence of speckles is most likely due to the fact that these
constructs do not properly bind to DNA.
On chromosomes Top1mt is less capable of DNA-
interaction and DNA-binding than Top1
We conclude from these experiments that the N-terminal
half of the DNA-binding core domain of Top1 (residues
191–351) suﬃces for conferring the complete mtDNA-
repressive eﬀect. However, downstream regions also play
a role, since C-terminal truncations, bearing the mtDNA-
repressive N-terminal sequence (i.e. MY-Top1
191–351 and
MY-Top1
191–659), did not cause mtDNA depletion (Figure
5C). The most likely reason for this is their lack of a
proper DNA clamping activity that prevents eﬃcient
mtDNA interaction. Moreover, hybrid enzymes where
the C-terminal half of the DNA-binding core domain of
Top1mt was replaced with a corresponding sequence of
Top1 (MY-Top1mt
1–187/Top1
352–765) induced mtDNA
depletion, although to a reduced extent (Figure 5B). In
summary, mtDNA-repressive properties of Top1 appear
to arise from the concerted action of the N- and
C-terminal halves of the DNA-binding core domain,
which together seem to form a tighter DNA clamp.
Consequently, one would expect that Top1mt has a
weaker DNA-binding activity than Top1. Consistently,
Top1mt can be extracted from mtDNA at lower salt con-
centration than Top1 from nuclear DNA (H.Zhang and
Y.Pommier, unpublished data). We therefore compared
binding of the enzymes with native chromatin, e.g.
chromosomes in living cells. To this end, we targeted
Top1mt to the cell nucleus by addition of an N-terminal
YFP-NLS tag (Y-NLS-Top1mt) and compared its local-
ization pattern with a corresponding Top1 construct
(Y-NLS-Top1
191–765). Y-NLS-Top1
191–765 was tightly
bound to chromosome during mitosis, as opposed to
Y-NLS-Top1mt (Figure 6A). Thus, Top1mt has a much
weaker capability to bind DNA than Top1 in a native
chromosomal context.
Chromosome interactions of Top1 and Top1mt are
determined by the core domains
Based on the diﬀerential capabilities of Top1 and Top1mt
to bind to chromosomal and mtDNA (Figures 5B and
6A), we speculated that the diﬀerent domain sequences
that confer the mtDNA-repressive potential also enable
Top1 to interact with and accumulate on mitotic
chromosomes. To test this, we targeted the Top1/
Top1mt hybrids used to study the contribution of the indi-
vidual enzyme domains on mtDNA depletion (Figure 5B)
to the cell nucleus and studied their accumulation on
mitotic chromosomes. Again, exchange of the linker and
C-terminal regions (Y-NLS-Top1mt
1–470/Top1
635–765)
that had not aﬀected mtDNA depletion in MY-Top1
also did not improve chromosome accumulation (Figure
6A and B). In contrast, an exchange in the middle of the
core domain combining the N-terminal half of the Top1mt
core with the C-terminal half of the Top1 core (Y-NLS-
Top1mt
1–187/Top1
352–765) or vice versa (Y-NLS-Top1
191–351/Top1mt
188–601) resulted in hybrid enzymes that
were clearly more concentrated on chromosomes than
Y-NLS-Top1mt but less concentrated than Y-NLS-
Top1
191–765 (Figure 6B). Because each enzyme equipped
with either half of the Top1 core domain has a capability
to interact with chromosomes that is half way between
Top1 and Top1mt, both halves of the core domain seem
to contribute equally to the interaction with metaphase
chromosomes. In summary, these data unambiguously
demonstrate that the capability of Top1 to interact with
chromosomes and the capability of Top1mt to securely
maintain mtDNA transcription and replication have
coevolved by structural modiﬁcations of those enzyme
domains that are crucial for DNA aﬃnity and clamping.
DISCUSSION
In this study, we investigated the meaning of the evolu-
tionary duplication of the TOP1 gene into nuclear (Top1)
and mitochondrial paralogs (Top1mt). This duplication is
conserved in all vertebrates, while invertebrate eukaryotes
do not possess a genetically distinct, mitochondria-
targeted version of the enzyme (7). This unique feature
suggests that Top1mt has a particular signiﬁcance for
mtDNA metabolism in vertebrates. However, Top1mt is
not essential for mouse development, even though its loss
may have still unknown negative eﬀects in the adult
mouse [H.Zhang and Y.Pommier, unpublished data;
(36)]. Thus, the existence of two topoisomerase I
paralogs could serve to improve the regulation of
Top1mt activity. Alternatively, specialized topoisomerase
Nucleic Acids Research, 2009,Vol.37, No. 19 6423I enzymes could be needed to meet divergent requirements
of the two genomes.
The ﬁndings presented here support the latter assump-
tion. The two enzyme paralogs of vertebrates have under-
gone functional specialization to such an extent that they
cannot substitute for each other, as opposed to the single
enzyme form in lower eukaryotes that provides topoiso-
merase I activity for both genomes. In yeast, mitochon-
drial overexpression of the single yeast topoisomerase I
is fully compatible with the maintenance of yeast
mtDNA (31), whereas we show here that in human cells,
mitochondrial targeting of Top1 is incompatible with
mtDNA maintenance. Conversely, nuclear targeting of
human Top1mt revealed that the mitochondrial enzyme
has lost the ability to interact properly with human
chromosomes.
Nonphysiological Top1mt protein levels and the result-
ing increase in topoisomerase I activity in the mitocho-
ndrial matrix had no eﬀect on mtDNA copy numbers,
suggesting that signiﬁcantly increased levels of the
mitochondria dedicated enzyme paralog are well tolerated.
Equivalent levels of the nuclear enzyme paralog in the
mitochondria induce complete loss of the mitochondrial
genome, although we cannot exclude that much lower
levels of Top1 in the mitochondria could be compatible
with mtDNA stability. This diﬀerence in tolerance shows
clearly that the functional properties of the two enzyme
paralogs diﬀer signiﬁcantly. Although the most prominent
structural diﬀerence between the two enzyme forms is
located in the N-terminal domain, this region is mainly
responsible for organelle-speciﬁc targeting (5,26), but not
involved in the functional diﬀerentiation of Top1 and
Top1mt. We mapped the divergent functional properties
of Top1 or Top1mt rather to the enzyme’s core domains
and found that the relevant structural deviations are
discrete and spread across the entire core region. The
most relevant alterations are located in the proximal half
of the core domain, i.e. residues 191–351 in Top1 (Figure
7B). Within this region, residues 215–351 (red colored
segment in Figure 7B) constitute a part of the upper
lobe of the DNA-clamp (a substructure formed by
residues 215–434 of Top1, yellow colored segment in
Figure 7A). Furthermore, residues 201–214 (green
colored segment in Figure 7B) regulate opening and
closing of the DNA clamp (2), where three clustered
tryptophan residues (Trp
203, 205, 206) seem to play a key
role (37). Hence, the N-terminal half of Top1’s core
domain crucially inﬂuences DNA-binding. Additionally,
C-terminal deletion mutants, which are inactive and
unable to properly clamp around the DNA double helix,
do also not repress mtDNA replication, further substan-
tiating our interpretation. In addition, mtDNA-repressive
properties are retained in Y723F mutants of Top1. This
mutant is also inactive, but has a fully operational DNA
clamp as well as normal DNA aﬃnity in vitro (38), and
hence possesses an undiminished propensity to interact
Figure 6. Interaction of Top1mt, Top1 and Top1mt/Top1 hybrids with metaphase chromosomes. (A) Confocal images of transmitted light (left)
and YFP ﬂuorescence (right) of living cells stably expressing Y-NLS-Top1mt and Y-NLS-Top1
191–765. Design of expressed construct is shown above.
(B) Confocal images of living cells stably expressing Y-NLS-Top1mt
1–470/Top1
635–765, Y-NLS-Top1mt
1–187/Top1
352–765 and Y-NLS-Top1
191–351/
Top1
188–601. Design of expressed construct is shown above.
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bound more loosely to mtDNA than Top1 to nuclear
DNA (H.Zhang and Y.Pommier, unpublished data) and
two out of the three tryptophan residues found to play a
key role in Top1 function (37) are not conserved in
Top1mt (5). Thus, modiﬁcations of the enzyme’s DNA
clamp are involved in making Top1mt compatible with
mtDNA. The same alterations also diminish the ability
of Top1mt to bind mitotic chromosomes. In summary,
this suggests that diﬀerent abilities of Top1 and Top1mt
to bind and clamp around DNA cause their divergent
functionality on nuclear and mtDNA. The enhanced
ability of Top1 to clamp around DNA appears necessary
for proper interaction with mitotic chromosomes but, on
the other hand, mediates repressive eﬀects on mtDNA.
Conversely, in Top1mt DNA binding seems reduced to
ascertain compatibility with mtDNA transcription and
replication at the cost of a proper function in the chromo-
some context. Ultimately, in vitro studies using
recombinant Top1 and Top1mt will be required to
discern in detail how and to what extent, DNA interaction
properties diﬀer between the two enzymes.
The dominant-negative eﬀect of Top1 constructs on
mtDNA replication is not without precedent. For
example, heterologous expression of mutated DNA
polymerase-g or Twinkle helicase strongly decreases
mtDNA copy number in HEK-293 cells (23,40,41).
However, the molecular events leading to mtDNA deple-
tion in this case appear to be quite diﬀerent. While
mutated Twinkle and DNA polymerase-g reduce
mtDNA copy number by severe replication stalling (23),
we demonstrate here by comparison with mtDNA
Figure 7. Ribbon diagram of the bi-loped structure of Top1 in covalent complex with DNA viewed with the DNA axis horizontally orientated (left)
or looking down the axis of the DNA (right). Diagrams are based on the X-ray crystal structure by Staker et al. (24) of a ternary complex of Top1,
DNA and TPT, which provides resolution of residues 201–765. TPT is omitted for clarity. (A) Representation of upper lobe in yellow, lower lobe in
magenta, the linker region in orange and the DNA in gray. The hinge region that opens and closes the enzyme around the DNA and the lips region
where the upper and lower lobes interact upon DNA binding are indicated. (B) Representation of the mtDNA repressive regions (residues 201–214
and 215–351) in green and red, respectively.
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Top1 is a repression of mtDNA transcription. Moreover,
time resolved analysis of mtDNA RIs indicates that
already initiated mtDNA replication proceeds in the
presence of Top1, whereas initiation of replication is
blocked. This suggests that Top1 depletes mtDNA by
inhibiting the RNA transcription necessary for mtDNA
replication and that mtDNA depletion is a secondary
eﬀect. Such a linkage between blockade of mtDNA tran-
scription and replication has also been observed in
Drosophila melanogaster Schneider cells upon knock
down of mitochondrial transcription factor B2, which
resulted in reduced mtDNA transcription and concomi-
tant decreases in mtDNA copy number (42).
While mtDNA depletion by mitochondria-targeted
Top1 is clearly linked to a repression of mitochondrial
RNA synthesis, the precise molecular mechanism of this
eﬀect can only be deduced by exclusion of unlikely
candidates. Clearly, mtDNA depletion is not a direct
response to altered mtDNA topology, as the Y723F
mutant incapable of removing supercoils from mtDNA
also inﬂicts mtDNA depletion. Given the multiple
indications of a stronger DNA binding, it is likely that
Top1 coats mtDNA in an obstructive manner, presenting
a physical barrier to the progression of the transcription
machinery. However, such obstructive coating should also
lead to replication stalling of which we found no signs in
cells expressing mitochondria-targeted Top1. Moreover,
this event should result in a faster decline of RNA
transcripts distal (e.g. COXI mRNA) rather than
proximal (e.g. 12S rRNA) to the initiation site, whereas
we observed identical time courses of decline for COXI
mRNA and 12S rRNA in cells expressing MY-Top1.
Because our results are inconsistent with a blockade of
transcription progression, repression of transcription
initiation is the most likely underlying mechanism.
This notion is corroborated by comparison of the
known eﬀects of Top1 on nuclear RNA transcription. In
yeast, Top1 facilitates nuclear RNA transcription by
removing transcription-generated supercoils during prolif-
eration (43), whereas it represses transcription during the
stationary growth phase of yeast (44). In reconstituted
transcription assays employing human RNA polymerase
II, human Top1 has been shown to act both as a cofactor
of activator-dependent transcription and a repressor of
basal transcription (45,46). The ability to repress tran-
scription is fully conserved in topoisomerase-inactive
Y723F mutants and hence independent of Top1 DNA
cleavage and relaxation activity. This transcriptional
repression is promoter-speciﬁc, which strongly indicates
a blockade of initiation as the underlying mechanism
(46). The similarities between the repressive eﬀects of
Top1 on RNA polymerase II transcription and mtDNA
transcription suggest a similar underlying mechanism,
namely repression of transcription initiation at the
promoter. The promoters for mtDNA transcription are
located in the major noncoding region of mtDNA that
also contains OH, the major origin of replication for
leading strand synthesis. This region also contains the reg-
ulatory displacement loop (D-loop) that is thought to be
involved in transcription and replication initiation as well
as nucleoid organization (10,47). Several proteins have
been described to bind speciﬁcally to the D-loop. In fact,
this structure attract and direct Top1mt, since Top1mt
cleavage sites are clustered downstream of the D-loop
(36). Thus, it is feasible that Top1 inhibits mtDNA
transcription by a dominant-negative interaction with
the D-loop region.
Whatever the precise mechanism of this dominant-
negative interaction may be, we clearly show that it is
associated with features that enhance the association of
Top1 with condensed chromatin DNA. Attenuation of
this property renders Top1mt compatible with mtDNA
metabolism. Interestingly, the reduced interaction with
condensed chromatin is a feature of all topoisomerases
found in mitochondria of vertebrates so far. In human,
alternative translation of the mRNA encoding topoiso-
merase Top3a creates mitochondrial Top3a or nuclear
Top3a (3). Incidentally, Top3a hardly interacts with
mitotic chromosomes (48) as opposed to Top3b that is
exclusively nuclear (49). Along the same lines, the only
Top2 found to be associated with mammalian mtDNA
appears to be a C-terminally truncated derivative of
nuclear Top2b (4), which again is the isoform that
hardly interacts with mitotic chromosomes as opposed
to Top2a (19,50).
These ﬁndings suggest that a divergence in chromatin
association is a common event during adaptation of
topoisomerases to divergent requirements in nuclear and
mitochondrial genomes of vertebrates. Our study clearly
shows that such a divergence of requirements must exist,
since it has incited the development of specialized topoiso-
merase I paralogs. However, the evolutionary driving
force directing the adaptation process remains unclear.
On the one hand, changes in the mtDNA transcription
process could have prompted the attenuation of DNA
association in Top1mt. On the other hand, an increased
complexity of the vertebrate nuclear DNA could have
necessitated the development of a more robust Top1,
which then became incompatible with mtDNA
transcription.
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